AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

651.433

+16.4832.60%

Number of Gainers:11

Number of Losers:10

Number of Flat:22

PE:- -

High:652.204

Open:632.825

Low:632.825

Close:634.950

Volume:47.54M

Turnover:129.24M

Market Cap:92.90B

Float Cap:89.72B

Loading ...

Australia's Monash IVF at over Four-Month High on Upbeat FY27 Outlook

CSL's U.S. Agreements Remove Two Stock Overhangs

Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors

MT Newswires Live

ASX Preview: Australian Shares to Fall as Oil Surges on US-Iran Conflict; Ausgold Fiscal 2026 Loss Narrows

MT Newswires Live

CSL Secures US Agreements to Cut Medicine Costs, Expand Manufacturing

MT Newswires Live

CSL Signs U.S. Government Agreements to Lower Drug Prices for Medicaid

CSL Limited-Agreements with U.S. on Drug Prices and Manufacturing

THOMSON REUTERS

CSL Ltd: Agreements Support Lower Prices for CSL Therapies and Reflect CSL's $1.5 Billion Plan to Expand Its U.S. Manufacturing Capacity in Illinois

THOMSON REUTERS

CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing

THOMSON REUTERS

CSL : Agreements Provide CSL with Additional Certainty Regarding Exposure to U.S. Drug Pricing & Certain Section 232 Tariffs

THOMSON REUTERS

CSL : Entered into Onshoring Agreement with the U.S. Department of Commerce

THOMSON REUTERS

CSL : Project to Substantially Increase Co's Ability to Produce Immunoglobulins & Albumin for People with Rare Diseases & Serious Conditions

THOMSON REUTERS

CSL Ltd: Project is Expected to Create at Least 300 New Pharmaceutical Manufacturing Jobs and Approximately 800 Construction and Related Jobs

THOMSON REUTERS

CSL : Does not Anticipate Any Material Impact During Fiscal Year 2027

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership

Simply Wall St.

High Growth Tech Stocks In Australia Echo IQ And 2 More To Watch

Simply Wall St.

ASX Stocks Estimated Below Intrinsic Value In August 2026

Simply Wall St.

Founder Led Stocks With Long Term Alignment Investors Should Watch

Simply Wall St.

Proteomics International Laboratories Posts FY Loss Attributable A$8.6 Million

Proteomics International Laboratories - FY Revenue A$3.6 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK7508/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":651.433,"timestamp":1789365599822,"preClose":634.9499,"halted":0,"volume":47539051,"delay":0,"changeRate":0.02596,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":16.483093,"latestTime":"09-14 16:00:00 AEST","open":632.8247,"high":652.2035,"low":632.8247,"amount":129241804,"amplitude":0.03052,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789344000000,1789365600000]],"turnoverRate":0.001864,"increases":13,"decrements":12,"flats":18,"marketCap":92903929115.25,"floatMarketCap":89720799305.375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":652.2035,"amplitude":0.03052,"preClose":634.9499,"low":632.8247,"latestPrice":651.433,"volume":47539051,"delay":0,"open":632.8247,"prevYearClose":644.3692,"prevWeekClose":634.95,"prevMonthClose":656.138,"prevQuarterClose":464.145,"fiveDayClose":661.74,"twentyDayClose":539.618,"sixtyDayClose":448.43,"secType":"PLATE","market":"AU","turnoverRate":0.001864,"marketCap":92903929115.25,"floatMarketCap":89720799305.375,"timestamp":1789365599822,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":11,"down":10,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664833759","title":"Australia's Monash IVF at over Four-Month High on Upbeat FY27 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2664833759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664833759?lang=en_us&edition=fundamental","pubTime":"2026-09-01 13:59","pubTimestamp":1788242381,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Monash IVF at over four-month high on upbeat FY27 outlook** Shares of Australia's Monash IVF GroupMVF.AXadvance as much as 12.3% to A$0.792, hitting their highest level since April 13** Stock extends gains after the fertility services provideroutlinesan upbeat FY27 outlook and declares a final dividend** Co says it expects FY27 performance to strengthen on market share gains, increased medical capacity and productivity initiatives** Adds, it plans to cut FY27 capital expenditure by about 50%** Co resumes dividends and declares a final dividend of 1.3 AU cents per share** Free cash flow improves to A$12.9 million from negative A$4.5 million a year earlier** YTD, stock up 4.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7113","MVF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887889","title":"CSL's U.S. Agreements Remove Two Stock Overhangs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887889","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887889?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:22","pubTimestamp":1788229320,"startTime":"0","endTime":"0","summary":"0222 GMT - CSL's U.S. agreements on drug pricing and manufacturing expansion remove two overhangs on the stock, Morgans analyst Derek Jellinek says. He tells clients in a note that the Australia-based pharmaceutical company has reinforced its competitive position as a major U.S. manufacturer of plasma-derived therapies. Jellinek sees the key positive of CSL's Medicaid pricing agreement as the improved visibility on exposure to potential U.S. drug-pricing reform. As for its onshoring agreement, he reckons it gives greater certainty with regard to tariff exposure. Morgans has a last-published buy rating on the stock and a target price of 187.71 Australian dollars. Shares are up 0.9% at A$173.07.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7511","CSL.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888926","title":"Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888926","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888926?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:24","pubTimestamp":1788222288,"startTime":"0","endTime":"0","summary":"Racura Oncology  said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1815336091.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2089985449.USD","IE00B19Z4B17.USD","BK7067","RAC.AU","BK7508","LU2931357623.SGD","LU0757428866.USD","AEIS","BK4157","LU0274383776.USD","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664899648","title":"ASX Preview: Australian Shares to Fall as Oil Surges on US-Iran Conflict; Ausgold Fiscal 2026 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2664899648","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664899648?lang=en_us&edition=fundamental","pubTime":"2026-09-01 08:12","pubTimestamp":1788221579,"startTime":"0","endTime":"0","summary":"Australian shares are poised to fall on Tuesday as oil prices surged more than 2.5% after renewed US-Iran military action heightened concerns over global supply disruptions and a prolonged conflict.Ov","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IOZ.AU","BBOZ.AU","BK7511","QFN.AU","VAS.AU","CSL.AU","BK7104","STW.AU","BEAR.AU","OZR.AU","IMLC.AU","OZF.AU","IIGF.AU","XKO.AU","XJO.AU","DACE.AU","E200.AU","QRE.AU","IISV.AU","XAO.AU","GEAR.AU","BK7508","VAP.AU","BK7067","EIGA.AU","ZYAU.AU","SLF.AU","GIVE.AU","BK7501","AUC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886424","title":"CSL Secures US Agreements to Cut Medicine Costs, Expand Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886424","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886424?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:29","pubTimestamp":1788218965,"startTime":"0","endTime":"0","summary":"CSL  has entered agreements with the US Administration to lower medicine costs and expand its manufacturing footprint in the US, according to a Tuesday Australian bourse filing.The company will provide Medicaid access to its medicines at prices comparable to those in other developed countries and extend similar pricing to newly launched therapies for all US payers under an agreement with the US Department of Health and Human Services, per the filing.The company has also entered into an onshoring agreement with the US Department of Commerce for its planned $1.5 billion expansion in Kankakee, Illinois, aimed at increasing production of plasma-derived therapies, the filing said.The company said the agreements are not expected to materially affect fiscal 2027 financial results, while providing greater certainty over US drug pricing and potential Section 232 tariff exposure, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7511","BK7501","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033885","title":"CSL Signs U.S. Government Agreements to Lower Drug Prices for Medicaid","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033885","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033885?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:28","pubTimestamp":1788215330,"startTime":"0","endTime":"0","summary":"CSL signs U.S. government agreements to lower drug prices for MedicaidCSL signed agreements with the US government to lower US drug prices, including Medicaid pricing comparable to other developed cou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLbfGxJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7511","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852458","title":"CSL Limited-Agreements with U.S. on Drug Prices and Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852458?lang=en_us&edition=fundamental","pubTime":"2026-09-01 06:17","pubTimestamp":1788214638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUE3CPQVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664701000","title":"CSL Ltd: Agreements Support Lower Prices for CSL Therapies and Reflect CSL's $1.5 Billion Plan to Expand Its U.S. Manufacturing Capacity in Illinois","url":"https://stock-news.laohu8.com/highlight/detail?id=2664701000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664701000?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664400070","title":"CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664400070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664400070?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664082000","title":"CSL : Agreements Provide CSL with Additional Certainty Regarding Exposure to U.S. Drug Pricing & Certain Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664082000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664082000?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7508","BK7511","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007000","title":"CSL : Entered into Onshoring Agreement with the U.S. Department of Commerce","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664007000?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7511","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000920","title":"CSL : Project to Substantially Increase Co's Ability to Produce Immunoglobulins & Albumin for People with Rare Diseases & Serious Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000920?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7508","BK7511","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000707","title":"CSL Ltd: Project is Expected to Create at Least 300 New Pharmaceutical Manufacturing Jobs and Approximately 800 Construction and Related Jobs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000707?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CSL.AU","BK7501","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000088","title":"CSL : Does not Anticipate Any Material Impact During Fiscal Year 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000088?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","CSL.AU","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664837618","title":"ASX Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2664837618","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664837618?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:08","pubTimestamp":1788203298,"startTime":"0","endTime":"0","summary":"As the S&P/ASX 200 reflects global market jitters with a predicted dip following Wall Street's inflation concerns, investors are keenly watching for opportunities in growth companies that demonstrate resilience and potential. In this environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those who know the company best, aligning management interests with shareholder value.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-16","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IIGF.AU","FRS.AU","BK7508","BK7501","VAP.AU","BK4505","IMLC.AU","IOZ.AU","EIQ.AU","IISV.AU","QFN.AU","BK7067","BK7095","BK7062","BEAR.AU","MSB.AU","STW.AU","BK4531","GEAR.AU","OZF.AU","PNI.AU","BK7104","BK7110","BK4108","IQ","AEM.AU","PDI.AU","XAO.AU","XKO.AU","WZR.AU","SKS.AU","DACE.AU","BK4526","QRE.AU","BK7017","SLF.AU","AWJ.AU","XJO.AU","TTT.AU","AR1.AU","BK7023","VAS.AU","OZR.AU","ZYAU.AU","SPL.AU","BK7093","BBOZ.AU","GIVE.AU","E200.AU","EIGA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883108","title":"High Growth Tech Stocks In Australia Echo IQ And 2 More To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883108","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883108?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:06","pubTimestamp":1788203178,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with inflation concerns mirroring Wall Street's recent performance, the S&P/ASX 200 is expected to open lower despite a positive close last week. In this environment of economic uncertainty and fluctuating indices, high-growth tech stocks like Echo IQ are gaining attention for their potential to thrive through innovation and adaptability, making them compelling options for investors seeking growth opportunities in a volatile market landscape.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/high-growth-tech-stocks-in-australia-echo-iq-and-2-more-to-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["STW.AU","BK7084","BEAR.AU","IMLC.AU","SLF.AU","EIGA.AU","DACE.AU","BK4526","GEAR.AU","IISV.AU","USD","OZR.AU","BBOZ.AU","IOZ.AU","E200.AU","EUFX","ZYAU.AU","XJO.AU","BK7508","XKO.AU","BK4108","VAS.AU","XAO.AU","EIQ.AU","GIVE.AU","BK7067","OZF.AU","BK7016","CROC","QRE.AU","MSB.AU","IQ","BK4531","VAP.AU","QFN.AU","ELS.AU","BK4552","BK7501","BK4505","IIGF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883100","title":"ASX Stocks Estimated Below Intrinsic Value In August 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883100","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883100?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:04","pubTimestamp":1788203070,"startTime":"0","endTime":"0","summary":"As the Australian market navigates the ripple effects of inflation concerns and potential interest rate hikes from the US, investors are keenly observing how these factors might influence local indices such as the S&P/ASX 200. Amidst this backdrop, identifying stocks that are potentially undervalued can offer opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/media/asx-sek/seek-shares/news/asx-stocks-estimated-below-intrinsic-value-in-august-2026-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/media/asx-sek/seek-shares/news/asx-stocks-estimated-below-intrinsic-value-in-august-2026-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","DECU","RGLO","BK7094","BK7095","STH.AU","TEA.AU","BK7137","VOTE","BK7016","LOV.AU","NXL.AU","JOYT","BK7078","PMDE","BMT.AU","BK7015","CAT.AU","BK7061","PNV.AU","BK7062","GXDW","SLC.AU","DMP.AU","BK7126","BK7084","SEK.AU","VGFPF","BK7055","NGI.AU","FEBU","BK7002","NIC.AU","LNW.AU","BK7128"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002013","title":"Founder Led Stocks With Long Term Alignment Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002013?lang=en_us&edition=fundamental","pubTime":"2026-08-31 23:22","pubTimestamp":1788189735,"startTime":"0","endTime":"0","summary":"With central banks signaling that interest rates may stay higher for longer, investors face a tougher backdrop for companies that rely on cheap capital and short term momentum. Founder led businesses often take a different path. Leaders with significant skin in the game tend to think in decades, not quarters. This article highlights 3 founder led stocks from our screener that show how this ownership mindset can shape long term opportunity.\nThe three founder led stocks in this article are only...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/founder-led-stocks-with-long-term-alignment-investors-should","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-maq/macquarie-technology-group-shares/news/founder-led-stocks-with-long-term-alignment-investors-should","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MQG.AU","BK7042","BK7067","BK7094","BK7511","BK7046","BK7043","BK7501","MAQ.AU","ISBC","BK4211","MSB.AU","BK7508","PME.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663784060","title":"Proteomics International Laboratories Posts FY Loss Attributable A$8.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663784060","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663784060?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:44","pubTimestamp":1788162262,"startTime":"0","endTime":"0","summary":"BRIEF-Proteomics International Laboratories Posts FY Loss Attributable A$8.6 MillionAug 31 -Proteomics International Laboratories LtdPIQ.AX:FY LOSS ATTRIBUTABLE A$8.6 MILLIONFY REVENUE A$3.6 MILLIONTHERE WERE NO DIVIDENDS PAID, RECOMMENDED OR DECLARED DURING CURRENT FINANCIAL PERIODFurther company coverage:PIQ.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R01J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIQ.AU","BK7048","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663272890","title":"Proteomics International Laboratories - FY Revenue A$3.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663272890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663272890?lang=en_us&edition=fundamental","pubTime":"2026-08-31 14:40","pubTimestamp":1788158409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R01J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","BK7508","PIQ.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":106,"code":"91000000","status":"200"}]}}